Publications by authors named "W Joseph Herring"
Objectives: Decision-analytic models assessing the value of emerging Alzheimer's disease (AD) treatments are challenged by limited evidence on short-term trial outcomes and uncertainty in extrapolating long-term patient-relevant outcomes. To improve understanding and foster transparency and credibility in modeling methods, we cross-compared AD decision models in a hypothetical context of disease-modifying treatment for mild cognitive impairment (MCI) due to AD.
Methods: A benchmark scenario (US setting) was used with target population MCI due to AD and a set of synthetically generated hypothetical trial efficacy estimates.
Importance: Delirium is common among older hospitalized adults. In addition to presenting immediate management issues, delirium can increase the long-term risk of dementia, institutionalization, and mortality. Delirium is associated with disrupted sleep, and prior studies suggest that some specific sleep-promoting agents may reduce delirium.
View Article and Find Full Text PDFArticle Synopsis
- - The study introduces the IPECAD open-source model framework, designed for economic evaluations of early Alzheimer's disease treatments, enhancing transparency and credibility in reimbursement decisions.
- - The model was validated against existing models and tested for various uncertainties, revealing that its findings on life-years and cost savings were significantly lower than those of other models like ICER and AD-ACE.
- - IPECAD exemplifies the potential of open-source research in health decision-making by allowing researchers to cross-validate and analyze uncertainties in treatment assessments, fostering an open science approach in Alzheimer's research.
Background And Objective: Gene therapies for sickle cell disease (SCD) may offer meaningful benefits for patients and society. This study evaluated the cost-effectiveness of lovotibeglogene autotemcel (lovo-cel), a one-time gene therapy administered via autologous hematopoietic stem cell transplantation, compared with common care for patients in the United States (US) with SCD aged ≥ 12 years with ≥ 4 vaso-occlusive events (VOEs) in the past 24 months.
Methods: We developed a patient-level simulation model accounting for lovo-cel and SCD-related events, complications, and mortality over a lifetime time horizon.
Policymakers in the United States (US) recommend coronavirus disease 2019 (COVID-19) vaccination with a monovalent 2023-2024 vaccine formulation based on the Omicron XBB.1.5 variant.
View Article and Find Full Text PDF